The molecular mechanisms responsible for this effect remain unclear, but the concurrent increase in these two proteins within the nucleus is correlated with malignancy of cancer cells and the combined targeting of ARF and MMP-7 may therefore have therapeutic value in the treatment of advanced prostate cancer. Here, CDKN2A is linked to cancer.